Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

68.68USD
10 Dec 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$68.68
Open
$70.00
Day's High
$70.00
Day's Low
$67.23
Volume
2,339,715
Avg. Vol
1,874,546
52-wk High
$110.80
52-wk Low
$66.62

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $108,911.00
Shares Outstanding(Mil.): 782.35
Dividend: --
Yield (%): --

Financials

  CELG.OQ Industry Sector
P/E (TTM): 43.29 31.13 33.63
EPS (TTM): 3.22 -- --
ROI: 10.08 15.55 15.02
ROE: 37.19 16.92 16.60

Amgen's AMG420 shows responses in myeloma trial, gets FDA fast track

SAN DIEGO Dec 3 Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, on Monday said seven out of ten patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

04 Dec 2018

Celgene's third-quarter results beat as Otezla sales soar

Celgene Corp on Thursday reported a better-than-expected third-quarter profit as sales of psoriasis drug Otezla and its flagship cancer medicine Revlimid surged, and the biotech company raised its full-year revenue forecast.

25 Oct 2018

UPDATE 2-Celgene's third-quarter results beat as Otezla sales soar

* Co hikes FY 2018 sales and adj. EPS forecast (Adds share movement, analyst comment, background, forecast details)

25 Oct 2018

Celgene posts 9.5 percent rise in third-quarter profit

Oct 25 Celgene Corp on Thursday reported a 9.5 percent increase in third-quarter profit, led by higher sales of its flagship cancer drug, Revlimid, and strong demand for psoriasis treatment Otezla.

25 Oct 2018

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

04 Sep 2018

UPDATE 1-Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

04 Sep 2018

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

04 Sep 2018

U.S. health secretary says agency can eliminate drug rebates

WASHINGTON U.S. Health and Human Services Secretary Alex Azar said it was within his agency's power to eliminate rebates on prescription drug purchases, a key element of the Trump administration's plan to lower prescription medicine costs. | Video

20 Aug 2018

Celgene profit tops expectations, will limit future price hikes

Celgene Corp on Thursday posted better-than-expected second quarter profit, powered by a 21 percent jump in sales of its blockbuster cancer drug Revlimid, and the U.S. biotech promised to limit future price increases on its medicines. The company joined several rivals in bowing to pressure from the administration of U.S. President Donald Trump to rein in rising costs of prescription drugs to U.S. patients.

26 Jul 2018

UPDATE 2-Celgene profit tops expectations, will limit future price hikes

* Revlimid sales beat Wall Street estimates (Adds company, analyst comment, background, share movement)

26 Jul 2018

Earnings vs. Estimates